Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive agreement for SI-613. Having completed Phase II study, the product is presently in Phase III clinical development for use in the knee, to be followed by clinical studies for hip, ankle, elbow and shoulder and a long-term safety evaluation.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive...
Seikagaku entered into a basic co-development and marketing collaboration with Ono Pharmaceutical in Japan for SI-613, an injectable hyaluronic acid + NSAID in development for the treatment of osteoarthritis.
The basic agreement is a preliminary step toward signing a definitive agreement for SI-613. Having completed Phase II study, the product is presently in Phase III clinical development for use in the knee, to be followed by clinical studies for hip, ankle, elbow and shoulder and a long-term safety evaluation.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
